Nasal Immunization Confers High Avidity Neutralizing Antibody Response and Immunity to Primary and Recurrent Genital Herpes in Guinea Pigs

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2017 Jan 14

PMID 28082979

Citations 7

Authors

Josefine Persson

Yuan Zhang

Thorunn A Olafsdottir

Karolina Thorn

Tina M Cairns

Frank Wegmann

Quentin J Sattentau

Roselyn J Eisenberg

Gary H Cohen

Ali M Harandi

Affiliations

Soon will be listed here.

Abstract

Genital herpes is one of the most prevalent sexually transmitted infections in both the developing and developed world. Following infection, individuals experience life-long latency associated with sporadic ulcerative outbreaks. Despite many efforts, no vaccine has yet been licensed for human use. Herein, we demonstrated that nasal immunization with an adjuvanted HSV-2 gD envelope protein mounts significant protection to primary infection as well as the establishment of latency and recurrent genital herpes in guinea pigs. Nasal immunization was shown to elicit specific T cell proliferative and IFN-γ responses as well as systemic and vaginal gD-specific IgG antibody (Ab) responses. Furthermore, systemic IgG Abs displayed potent HSV-2 neutralizing properties and high avidity. By employing a competitive surface plasmon resonance (SPR) analysis combined with a battery of known gD-specific neutralizing monoclonal Abs (MAbs), we showed that nasal immunization generated IgG Abs directed to two major discontinuous neutralizing epitopes of gD. These results highlight the potential of nasal immunization with an adjuvanted HSV-2 envelope protein for induction of protective immunity to primary and recurrent genital herpes.

Citing Articles

Intranasal SARS-CoV-2 spike-based immunisation adjuvanted with polyethyleneimine elicits mucosal and systemic humoral responses in mice.

Deimel L, Liu X, Gilbert-Jaramillo J, Liu S, James W, Sattentau Q J Immunol Methods. 2022; 511:113380.

PMID: 36306825 PMC: 9597555. DOI: 10.1016/j.jim.2022.113380.

PEDV infection in neonatal piglets through the nasal cavity is mediated by subepithelial CD3 T cells.

Yuan C, Jin Y, Li Y, Zhang E, Zhang P, Yang Q Vet Res. 2021; 52(1):26.

PMID: 33597007 PMC: 7888150. DOI: 10.1186/s13567-020-00883-w.

Development of a Novel Assay to Assess the Avidity of Dengue Virus-Specific Antibodies Elicited in Response to a Tetravalent Dengue Vaccine.

Tsuji I, Dominguez D, Egan M, Dean H J Infect Dis. 2021; 225(9):1533-1544.

PMID: 33534885 PMC: 9071338. DOI: 10.1093/infdis/jiab064.

Comparative models for human nasal infections and immunity.

Casadei E, Salinas I Dev Comp Immunol. 2018; 92:212-222.

PMID: 30513304 PMC: 7102639. DOI: 10.1016/j.dci.2018.11.022.

Acute Infection and Subsequent Subclinical Reactivation of Herpes Simplex Virus 2 after Vaginal Inoculation of Rhesus Macaques.

Lo M, Zhu J, Hansen S, Carroll T, Farr Zuend C, Noel-Romas L J Virol. 2018; 93(2).

PMID: 30333177 PMC: 6321901. DOI: 10.1128/JVI.01574-18.

References

Whitbeck J, Huang Z, Cairns T, Gallagher J, Lou H, Ponce-de-Leon M . Repertoire of epitopes recognized by serum IgG from humans vaccinated with herpes simplex virus 2 glycoprotein D. J Virol. 2014; 88(14):7786-95. PMC: 4097771. DOI: 10.1128/JVI.00544-14. View

Belshe R, Leone P, Bernstein D, Wald A, Levin M, Stapleton J . Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med. 2012; 366(1):34-43. PMC: 3287348. DOI: 10.1056/NEJMoa1103151. View

Belshe R, Heineman T, Bernstein D, Bellamy A, Ewell M, van der Most R . Correlate of immune protection against HSV-1 genital disease in vaccinated women. J Infect Dis. 2013; 209(6):828-36. PMC: 3935479. DOI: 10.1093/infdis/jit651. View

Bowen J, Alpar H, Phillpotts R, Brown M . Mucosal delivery of herpes simplex virus vaccine. Res Virol. 1992; 143(4):269-78. DOI: 10.1016/s0923-2516(06)80115-9. View

Bertke A, Patel A, Imai Y, Apakupakul K, Margolis T, Krause P . Latency-associated transcript (LAT) exon 1 controls herpes simplex virus species-specific phenotypes: reactivation in the guinea pig genital model and neuron subtype-specific latent expression of LAT. J Virol. 2009; 83(19):10007-15. PMC: 2748022. DOI: 10.1128/JVI.00559-09. View

Khanna K, Bonneau R, Kinchington P, Hendricks R . Herpes simplex virus-specific memory CD8+ T cells are selectively activated and retained in latently infected sensory ganglia. Immunity. 2003; 18(5):593-603. PMC: 2871305. DOI: 10.1016/s1074-7613(03)00112-2. View

Del Campo J, Lindqvist M, Cuello M, Backstrom M, Cabrerra O, Persson J . Intranasal immunization with a proteoliposome-derived cochleate containing recombinant gD protein confers protective immunity against genital herpes in mice. Vaccine. 2009; 28(5):1193-200. DOI: 10.1016/j.vaccine.2009.11.035. View

Lee C, Lin L, Chan W, Ko T, Lai J, Wang A . Structural basis for the antibody neutralization of herpes simplex virus. Acta Crystallogr D Biol Crystallogr. 2013; 69(Pt 10):1935-45. PMC: 3792640. DOI: 10.1107/S0907444913016776. View

Chu C, Meador M, Young C, Strasser J, Bourne N, Milligan G . Antibody-mediated protection against genital herpes simplex virus type 2 disease in mice by Fc gamma receptor-dependent and -independent mechanisms. J Reprod Immunol. 2007; 78(1):58-67. PMC: 2441821. DOI: 10.1016/j.jri.2007.08.004. View

10.

Bourne N, Pyles R, Bernstein D, Stanberry L . Modification of primary and recurrent genital herpes in guinea pigs by passive immunization. J Gen Virol. 2002; 83(Pt 11):2797-2801. DOI: 10.1099/0022-1317-83-11-2797. View

11.

Bernstein D . Effect of route of vaccination with vaccinia virus expressing HSV-2 glycoprotein D on protection from genital HSV-2 infection. Vaccine. 2000; 18(14):1351-8. DOI: 10.1016/s0264-410x(99)00416-8. View

12.

Skoberne M, Cardin R, Lee A, Kazimirova A, Zielinski V, Garvie D . An adjuvanted herpes simplex virus 2 subunit vaccine elicits a T cell response in mice and is an effective therapeutic vaccine in Guinea pigs. J Virol. 2013; 87(7):3930-42. PMC: 3624190. DOI: 10.1128/JVI.02745-12. View

13.

Nicola A, Ponce de Leon M, Xu R, Hou W, Whitbeck J, Krummenacher C . Monoclonal antibodies to distinct sites on herpes simplex virus (HSV) glycoprotein D block HSV binding to HVEM. J Virol. 1998; 72(5):3595-601. PMC: 109580. DOI: 10.1128/JVI.72.5.3595-3601.1998. View

14.

Atanasiu D, Saw W, Cohen G, Eisenberg R . Cascade of events governing cell-cell fusion induced by herpes simplex virus glycoproteins gD, gH/gL, and gB. J Virol. 2010; 84(23):12292-9. PMC: 2976417. DOI: 10.1128/JVI.01700-10. View

15.

Rupp R, Bernstein D . The potential impact of a prophylactic herpes simplex vaccine. Expert Opin Emerg Drugs. 2008; 13(1):41-52. DOI: 10.1517/14728214.13.1.41. View

16.

McLean C, Erturk M, Jennings R, Challanain D, Minson A, Duncan I . Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1. J Infect Dis. 1994; 170(5):1100-9. DOI: 10.1093/infdis/170.5.1100. View

17.

Tayyari F, Sutton T, Manson H, Hegele R . CpG-oligodeoxynucleotides inhibit RSV-enhanced allergic sensitisation in guinea pigs. Eur Respir J. 2005; 25(2):295-302. DOI: 10.1183/09031936.05.00016304. View

18.

Wizel B, Persson J, Thorn K, Nagy E, Harandi A . Nasal and skin delivery of IC31(®)-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes. Vaccine. 2012; 30(29):4361-8. DOI: 10.1016/j.vaccine.2012.02.019. View

19.

Ugozzoli M, OHagan D, Ott G . Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: the effect of adjuvants on mucosal and serum antibody responses. Immunology. 1998; 93(4):563-71. PMC: 1364136. DOI: 10.1046/j.1365-2567.1998.00441.x. View

20.

Muggeridge M, Isola V, Byrn R, Tucker T, Minson A, Glorioso J . Antigenic analysis of a major neutralization site of herpes simplex virus glycoprotein D, using deletion mutants and monoclonal antibody-resistant mutants. J Virol. 1988; 62(9):3274-80. PMC: 253447. DOI: 10.1128/JVI.62.9.3274-3280.1988. View